Mikael Knip1,2,3,4,5, Jarno Honkanen6,7. 1. Children's Hospital, University of Helsinki, P.O. Box 22, (Stenbäckinkatu 11), FI, -00014, Helsinki, Finland. mikael.knip@helsinki.fi. 2. Children's Hospital, Helsinki University Hospital, Helsinki, Finland. mikael.knip@helsinki.fi. 3. Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland. mikael.knip@helsinki.fi. 4. Folkhälsan Research Center, Helsinki, Finland. mikael.knip@helsinki.fi. 5. Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland. mikael.knip@helsinki.fi. 6. Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland. 7. Clinicum, University of Helsinki, Helsinki, Finland.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to summarize potential modulations of the intestinal microbiome aimed at preventing or delaying progression to overt type 1 diabetes in the light of recently identified perturbations of the gut microbiota associated with the development of type 1 diabetes. RECENT FINDINGS: Accumulated data suggest that the gut microbiota is involved at two different steps in the evolution of type 1 diabetes. At the first step, the intestinal tract is colonized by a microbial community unable to provide an adequate education of the immune system. As a consequence, the infant acquires susceptibility to immune-mediated diseases, type 1 diabetes included. At the other step, the young child seroconverts to positivity for diabetes-associated autoantibodies. This is preceded or accompanied by a decrease in the diversity of the intestinal microbiota and an increased abundance of Bacteroides species. These changes will affect the disease process promoting progression toward overt type 1 diabetes. By providing specific probiotics, one can affect the colonization of the intestinal tract in the newborn infant or strengthen the immune education in early life. Human milk oligosaccharides function as nutrients for "healthy" bacteria. Dietary interventions applying modified starches can influence the numbers and activities of both autoreactive and regulatory T cells and provide protection against autoimmune diabetes in non-obese diabetic mice. Modulation of the intestinal microbiome holds the promise of effective protection against human type 1 diabetes.
PURPOSE OF REVIEW: The purpose of this review is to summarize potential modulations of the intestinal microbiome aimed at preventing or delaying progression to overt type 1 diabetes in the light of recently identified perturbations of the gut microbiota associated with the development of type 1 diabetes. RECENT FINDINGS: Accumulated data suggest that the gut microbiota is involved at two different steps in the evolution of type 1 diabetes. At the first step, the intestinal tract is colonized by a microbial community unable to provide an adequate education of the immune system. As a consequence, the infant acquires susceptibility to immune-mediated diseases, type 1 diabetes included. At the other step, the young child seroconverts to positivity for diabetes-associated autoantibodies. This is preceded or accompanied by a decrease in the diversity of the intestinal microbiota and an increased abundance of Bacteroides species. These changes will affect the disease process promoting progression toward overt type 1 diabetes. By providing specific probiotics, one can affect the colonization of the intestinal tract in the newborn infant or strengthen the immune education in early life. Human milk oligosaccharides function as nutrients for "healthy" bacteria. Dietary interventions applying modified starches can influence the numbers and activities of both autoreactive and regulatory T cells and provide protection against autoimmune diabetes in non-obese diabeticmice. Modulation of the intestinal microbiome holds the promise of effective protection against humantype 1 diabetes.
Entities:
Keywords:
Diet; Microbiome; Microbiota; Prebiotics; Probiotics; Type 1 diabetes
Authors: Colin Hill; Francisco Guarner; Gregor Reid; Glenn R Gibson; Daniel J Merenstein; Bruno Pot; Lorenzo Morelli; Roberto Berni Canani; Harry J Flint; Seppo Salminen; Philip C Calder; Mary Ellen Sanders Journal: Nat Rev Gastroenterol Hepatol Date: 2014-06-10 Impact factor: 46.802
Authors: Andreas Sturm; Klaus Rilling; Daniel C Baumgart; Konstantinos Gargas; Tay Abou-Ghazalé; Bärbel Raupach; Jana Eckert; Ralf R Schumann; Corinne Enders; Ulrich Sonnenborn; Bertram Wiedenmann; Axel U Dignass Journal: Infect Immun Date: 2005-03 Impact factor: 3.441
Authors: Christopher T Brown; Austin G Davis-Richardson; Adriana Giongo; Kelsey A Gano; David B Crabb; Nabanita Mukherjee; George Casella; Jennifer C Drew; Jorma Ilonen; Mikael Knip; Heikki Hyöty; Riitta Veijola; Tuula Simell; Olli Simell; Josef Neu; Clive H Wasserfall; Desmond Schatz; Mark A Atkinson; Eric W Triplett Journal: PLoS One Date: 2011-10-17 Impact factor: 3.240
Authors: Richard K Le Leu; Jean M Winter; Claus T Christophersen; Graeme P Young; Karen J Humphreys; Ying Hu; Silvia W Gratz; Rosalind B Miller; David L Topping; Anthony R Bird; Michael A Conlon Journal: Br J Nutr Date: 2015-06-17 Impact factor: 3.718
Authors: Michael T Leonard; Austin G Davis-Richardson; Alexandria N Ardissone; Kaisa M Kemppainen; Jennifer C Drew; Jorma Ilonen; Mikael Knip; Olli Simell; Jorma Toppari; Riitta Veijola; Heikki Hyöty; Eric W Triplett Journal: Front Microbiol Date: 2014-07-17 Impact factor: 5.640
Authors: Vit Neuman; Ondrej Cinek; David P Funda; Tomas Hudcovic; Jaroslav Golias; Lenka Kramna; Lenka Petruzelkova; Stepanka Pruhova; Zdenek Sumnik Journal: Diabetologia Date: 2019-04-25 Impact factor: 10.122
Authors: Bethany M Henrick; Andra A Hutton; Michelle C Palumbo; Giorgio Casaburi; Ryan D Mitchell; Mark A Underwood; Jennifer T Smilowitz; Steven A Frese Journal: mSphere Date: 2018-03-07 Impact factor: 4.389